Shuttle Pharmaceuticals Files 8-K Amid Listing Concerns
Ticker: SHPH · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Jan 7, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting-risk, listing-standards, regulatory-filing
TL;DR
Shuttle Pharma 8-K: Delisting concerns and other events as of Dec 31, 2024.
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on January 7, 2025, reporting events as of December 31, 2024. The filing indicates a potential notice of delisting or failure to meet continued listing standards, along with other events and financial statements. The company is incorporated in Delaware and its principal executive offices are located in Gaithersburg, MD.
Why It Matters
This filing signals potential issues with Shuttle Pharmaceuticals' continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — The mention of 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' indicates significant risk to the company's stock trading status.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- December 31, 2024 (date) — Date of earliest event reported
- January 7, 2025 (date) — Date of report
- Gaithersburg, MD (location) — Principal executive offices
FAQ
What specific listing rule or standard has Shuttle Pharmaceuticals Holdings, Inc. potentially failed to satisfy?
The filing does not specify the exact listing rule or standard that has potentially been violated, only that a notice regarding this issue has been filed.
What are the 'Other Events' mentioned in the filing?
The filing does not detail the specific 'Other Events' beyond the notice of delisting concerns and the filing of financial statements and exhibits.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 31, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
What is the Commission File Number for Shuttle Pharmaceuticals Holdings, Inc.?
The Commission File Number for Shuttle Pharmaceuticals Holdings, Inc. is 001-41488.
Filing Stats: 876 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2025-01-07 09:00:30
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
- $1.00 — maintain a minimum closing bid price of $1.00 per share, as required for continued li
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex99-1.htm (EX-99.1) — 12KB
- 0001493152-25-001132.txt ( ) — 230KB
- shph-20241231.xsd (EX-101.SCH) — 3KB
- shph-20241231_lab.xml (EX-101.LAB) — 33KB
- shph-20241231_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Dated: January 7, 2025 By: /s/ Anatoly Dritschilo Name: Anatoly Dritschilo Title: Chief Executive Officer